Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Abeona Therapeutics Inc (NASDAQ: ABEO) closed the day trading at $5.37 down -1.47% from the previous closing price of $5.45. In other words, the price has decreased by -$1.47 from its previous closing price. On the day, 0.89 million shares were traded. ABEO stock price reached its highest trading level at $5.4473 during the session, while it also had its lowest trading level at $5.21.
Ratios:
For a better understanding of ABEO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.74. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.09.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 29 ’25 when Seshadri Vishwas sold 25,000 shares for $5.31 per share. The transaction valued at 132,740 led to the insider holds 1,164,818 shares of the business.
Seshadri Vishwas bought 25,000 shares of ABEO for $132,695 on Dec 29 ’25. On Nov 13 ’25, another insider, Alvino Mark, who serves as the Director of the company, sold 15,000 shares for $4.74 each. As a result, the insider received 71,168 and left with 62,252 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 291007584 and an Enterprise Value of 107997608. As of this moment, Abeona’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 727.51 while its Price-to-Book (P/B) ratio in mrq is 1.64. Its current Enterprise Value per Revenue stands at 269.994 whereas that against EBITDA is -1.334.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.12, which has changed by -0.02154398 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.54, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is 8.79%, while the 200-Day Moving Average is calculated to be -5.09%.
Shares Statistics:
Over the past 3-months, ABEO traded about 1.71M shares per day on average, while over the past 10 days, ABEO traded about 1082810 shares per day. A total of 52.40M shares are outstanding, with a floating share count of 49.46M. Insiders hold about 8.73% of the company’s shares, while institutions hold 62.41% stake in the company. Shares short for ABEO as of 1765756800 were 13998273 with a Short Ratio of 8.19, compared to 1763078400 on 13589078. Therefore, it implies a Short% of Shares Outstanding of 13998273 and a Short% of Float of 27.54.
Earnings Estimates
The performance of Abeona Therapeutics Inc (ABEO) in the stock market is under the watchful eye of 3.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.05 and low estimates of -$0.15.
Analysts are recommending an EPS of between $1.33 and -$1.6 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.07, with 3.0 analysts recommending between $0.2 and -$0.36.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $18.67M. There is a high estimate of $24.9M for the next quarter, whereas the lowest estimate is $9.6M. Based on 7 analysts’ estimates, the company’s revenue will be $112.09M in the next fiscal year. The high estimate is $140.3M and the low estimate is $79.84M.
